Cover Image
市場調查報告書

全球搭配診斷市場趨勢,機會分析,市場佔有率與預測

Global Companion Diagnostics Market Insights, Opportunity Analysis, Market Shares and Forecast 2017-2024

出版商 Occams Business Research & Consulting Pvt. Ltd. 商品編碼 603521
出版日期 內容資訊 英文 190 Pages
商品交期: 請詢問到貨日
價格
Back to Top
全球搭配診斷市場趨勢,機會分析,市場佔有率與預測 Global Companion Diagnostics Market Insights, Opportunity Analysis, Market Shares and Forecast 2017-2024
出版日期: 2018年08月31日 內容資訊: 英文 190 Pages
簡介

本報告提供全球搭配診斷市場相關調查,彙整市場現狀與今後的預測,各市場區隔趨勢,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 市場概要

  • 全球市場:發展與變遷
  • 市場定義和範圍
  • 產業結構
  • 市場整體分析
  • 預測分析
  • 策略性分析
  • 競爭分析
  • 策略性建議與主要的結論

第3章 市場決策因素

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 市場課題

第4章 市場區隔

  • 產品與服務
  • 各技術
  • 各適應症
  • 各終端用戶

第5章 競爭環境

  • 主要策略
    • 合併·收購
    • 合資企業
    • 產品上市
    • 聯盟

第6章 各地區分析

  • 支持決策的資料庫與預測技術
  • 比較分析
  • 機會矩陣
  • 各地區市場
    • 北美
    • 歐洲
    • 亞太地區
    • 其他各國

第7章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: HAD-8431117

The global companion diagnostics market is expected to grow at a CAGR of over 20.1% during the period of 2016-2023. Companion diagnostic tests are used for collecting patient information, dosing requirement, and susceptibility regarding the side effects of any particular drug. Companion diagnostics tests are also known as pharmacogenetic tests. While many drug labels provide guidance on pharmacogenetic testing, certain drugs specifically cancer drugs, require patients to receive a diagnostic test, as the efficacy of these drugs is limited to those with a particular genotype. Major driving forces of companion diagnostics are improved regulatory guidelines, rising cancer incidence across the globe, need for targeted therapies, and increasing collaborations and partnerships for test development. The companion diagnostics market is fastest growing segments of the IVD and clinical lab services markets. United States, over half of all FDA approvals for companion diagnostics have occurred since 2010. The closely associated pharmacodiagnostics IVD market is expected to grow annually by over 20%. Approval of CDX- assisted therapies, and high growth of market opened for laboratory tests and IVD products. Global companion diagnostics is facing challenges as prolonged development time of companion diagnostics, increasing duration of the approval, in spite of all challenges there are huge opportunities as process increasing new indication areas, increasing demand for next-generation sequencing, increasing number of clinical trials which will leverage the market of data fabric. 

The global companion diagnostics market is segmented on the basis of product & services, indication, technology and end user. Indication segment consist of oncology, cardiovascular conditions, central nervous system indications, inflammation and virology segment. Oncology is dominating the indication segment. Technology market is segmented as Immunohistochemistry and Molecular diagnostics etc. Molecular diagnostics is the fastest growing and highest revenue generator product & service segment consist of assay kits, reagents, and software & services. End user segment of market is differentiate into pharmaceutical & biopharmaceutical companies, reference laboratories, and other end users. The pharmaceutical and biopharmaceutical companies segment is dominating the market during the forecasted period.

Geographically North America hold the largest share in companion diagnostics market, due to the high technological advancements in the region. Asia Pacific market is expected to grow at the highest CAGR between 2016 and 2023. The primary forces which are driving growth of the market are the growing prevalence diseases like cancer and neurology diseases, also increasing number of hospitals and diagnostics laboratories are creating huge opportunity which is driving the growth of the companion diagnostics market.

The growth in global companion diagnostics market is also influenced by the presence of major players such Qiagen n.v. (Netherland), Thermo Fisher Scientific Inc. (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Genomic Health, Inc. (US) and other. Collaborations and partnership etc. are some crucial strategies adopted by the major players to gain competitive advantage.

Table of Contents

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. GLOBAL COMPANION DIAGNOSTIC MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. TOTAL MARKET ANALYSIS
    • 2.4.1. TOP 5 FINDINGS
    • 2.4.2. TOP 5 OPPORTUNITY MARKETS
    • 2.4.3. TOP 5 COMPANIES
    • 2.4.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.5. ESTIMATION ANALYSIS
  • 2.6. STRATEGIC ANALYSIS
    • 2.6.1. INVESTMENT VS. ADOPTION MODEL
    • 2.6.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.6.3. PORTERS 5 FORCE MODEL
    • 2.6.4. SEE-SAW ANALYSIS
    • 2.6.5. ROI ANALYSIS
    • 2.6.6. GAP ANALYSIS
    • 2.6.7. PATENT ANALYSIS
    • 2.6.8. PRICING ANALYSIS
    • 2.6.9. PIPELINE ANALYSIS
    • 2.6.10. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.7. COMPETITIVE ANALYSIS
    • 2.7.1. KEY STRATEGIES & ANALYSIS
    • 2.7.2. MARKET SHARE ANALYSIS AND TOP MARKET ANALYSIS
  • 2.8. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.8.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.8.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.8.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. IMPROVEMENTS IN REGULATORY GUIDELINES
    • 3.1.2. GROWING NEED FOR TARGETED THERAPIES
    • 3.1.3. RISING CANCER INCIDENCE ACROSS THE GLOBE
    • 3.1.4. INCREASING PARTNERSHIPS AND COLLABORATIONS FOR COMPANION DIAGNOSTICS TEST DEVELOPMENT
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. UNFAVORABLE REIMBURSEMENT SCENARIO
    • 3.2.2. INTELLECTUAL PROPERTY RIGHTS PROTECTION ISSUES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. INCREASING NEW INDICATION AREAS
    • 3.3.2. INCREASING DEMAND FOR NEXT-GENERATION SEQUENCING
    • 3.3.3. INCREASING NUMBER OF CLINICAL TRIALS
  • 3.4. MARKET CHALLENGES
    • 3.4.1. PROLONGED DEVELOPMENT TIME OF COMPANION DIAGNOSTICS
    • 3.4.2. INCREASING DURATION OF THE APPROVAL PROCESS

4. MARKET SEGMENTATION

  • 4.1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE
    • 4.1.1. MARKET DEFINITION AND SCOPE
    • 4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.4. OPPORTUNITY MATRIX
    • 4.1.5. MARKET SEGMENTATION
      • 4.1.5.1. GLOBAL ASSAY KITS AND REAGENTS MARKET
        • 4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.1.4. KEY CONCLUSIONS
      • 4.1.5.2. GLOBAL SOFTWARE AND SERVICE MARKET
        • 4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.1.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.1.5.2.4. KEY CONCLUSIONS
  • 4.2. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. GLOBAL IN SITU HYBRIDIZATION MARKET
        • 4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.1.4. KEY CONCLUSIONS
      • 4.2.5.2. GLOBAL POLYMERASE CHAIN REACTION MARKET
        • 4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.2.4. KEY CONCLUSIONS
      • 4.2.5.3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET
        • 4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.3.4. KEY CONCLUSIONS
      • 4.2.5.4. GLOBAL NEXT GENERATION SEQUENCING MARKET
        • 4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.4.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.4.4. KEY CONCLUSIONS
      • 4.2.5.5. GLOBAL OTHER TECHNOLOGIES MARKET
        • 4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.5.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.2.5.5.3. KEY PLAYERS & KEY PRODUCTS
        • 4.2.5.5.4. KEY CONCLUSIONS
  • 4.3. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. GLOBAL ONCOLOGY MARKET
        • 4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.1.4. KEY CONCLUSIONS
      • 4.3.5.2. GLOBAL NEUROLOGY MARKET
        • 4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.2.4. KEY CONCLUSIONS
      • 4.3.5.3. GLOBAL INFECTIOUS DISEASES MARKET
        • 4.3.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.3.4. KEY CONCLUSIONS
      • 4.3.5.4. GLOBAL OTHER INDICATIONS MARKET
        • 4.3.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.3.5.4.3. KEY PLAYERS & KEY PRODUCTS
        • 4.3.5.4.4. KEY CONCLUSIONS
  • 4.4. GLOBAL COMPANION DIAGNOSTIC MARKET, BY END USER
    • 4.4.1. MARKET DEFINITION AND SCOPE
    • 4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.4.4. OPPORTUNITY MATRIX
    • 4.4.5. MARKET SEGMENTATION
      • 4.4.5.1. GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET
        • 4.4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.4.5.1.3. KEY PLAYERS & KEY PRODUCTS
        • 4.4.5.1.4. KEY CONCLUSIONS
      • 4.4.5.2. GLOBAL REFERENCE LABORATORIES MARKET
        • 4.4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.4.5.2.3. KEY PLAYERS & KEY PRODUCTS
        • 4.4.5.2.4. KEY CONCLUSION
      • 4.4.5.3. GLOBAL OTHER END USER MARKET
        • 4.4.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.3.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
        • 4.4.5.3.3. KEY PLAYERS & KEY PRODUCTS
        • 4.4.5.3.4. KEY CONCLUSION

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF MERGERS AND ACQUISITION
    • 5.1.2. LIST OF JOINT VENTURES
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIPS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GLOBAL COMPANION DIAGNOSTIC MARKET BY REGION 2014-2023($ MILLION)
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.1.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.1.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. RUSSIA
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. REST OF EUROPE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.2.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.3.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. AUSTRALIA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.4.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. REST OF ASIA PACIFIC
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.3.2.5.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY ANALYSIS 2014-2023($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.4.2.1.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023($ MILLION)
          • 6.4.4.2.2.2. KEY PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. F. HOFFMANN-LA ROCHE AG (SWITZERLAND)
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. STRATEGIC INITIATIVES
    • 7.1.4. SCOT ANALYSIS
    • 7.1.5. STRATEGIC ANALYSIS
  • 7.2. AGILENT TECHNOLOGIES, INC. (U.S.)
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. STRATEGIC INITIATIVES
    • 7.2.4. SCOT ANALYSIS
    • 7.2.5. STRATEGIC ANALYSIS
  • 7.3. QIAGEN N.V. (NETHERLANDS)
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. STRATEGIC INITIATIVES
    • 7.3.4. SCOT ANALYSIS
    • 7.3.5. STRATEGIC ANALYSIS
  • 7.4. THERMO FISHER SCIENTIFIC INC. (U.S.)
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. STRATEGIC INITIATIVES
    • 7.4.4. SCOT ANALYSIS
    • 7.4.5. STRATEGIC ANALYSIS
  • 7.5. ABBOTT LABORATORIES, INC. (U.S.)
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. STRATEGIC INITIATIVES
    • 7.5.4. SCOT ANALYSIS
    • 7.5.5. STRATEGIC ANALYSIS
  • 7.6. MYRIAD GENETICS, INC. (U.S.)
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. STRATEGIC INITIATIVES
    • 7.6.4. SCOT ANALYSIS
    • 7.6.5. STRATEGIC ANALYSIS
  • 7.7. DANAHER CORPORATION (U.S.)
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. STRATEGIC INITIATIVES
    • 7.7.4. SCOT ANALYSIS
    • 7.7.5. STRATEGIC ANALYSIS
  • 7.8. ALMAC GROUP (U.S.)
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. STRATEGIC INITIATIVES
    • 7.8.4. SCOT ANALYSIS
    • 7.8.5. STRATEGIC ANALYSIS
  • 7.9. SYSMEX CORPORATION (JAPAN)
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. STRATEGIC INITIATIVES
    • 7.9.4. SCOT ANALYSIS
    • 7.9.5. STRATEGIC ANALYSIS
  • 7.10. GENOMIC HEALTH, INC. (U.S.)
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. STRATEGIC INITIATIVES
    • 7.10.4. SCOT ANALYSIS
    • 7.10.5. STRATEGIC ANALYSIS
  • 7.11. GE HEALTHCARE LTD(US)
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. STRATEGIC INITIATIVES
    • 7.11.4. SCOT ANALYSIS
    • 7.11.5. STRATEGIC ANALYSIS
  • 7.12. LIFE TECHNOLOGIES CORPORATION (U.S.)
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. STRATEGIC INITIATIVES
    • 7.12.4. SCOT ANALYSIS
    • 7.12.5. STRATEGIC ANALYSIS
  • 7.13. DANAHER CORPORATION (U.S.)
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. STRATEGIC INITIATIVES
    • 7.13.4. SCOT ANALYSIS
    • 7.13.5. STRATEGIC ANALYSIS
  • 7.14. ILLUMINA, INC (U.S.)
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. STRATEGIC INITIATIVES
    • 7.14.4. SCOT ANALYSIS
    • 7.14.5. STRATEGIC ANALYSIS
  • 7.15. ARUP LABORATORIES INC (U.S.)
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. STRATEGIC INITIATIVES
    • 7.15.4. SCOT ANALYSIS
    • 7.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • 1. GLOBAL COMPANION DIAGNOSTIC MARKET BY PRODUCT AND SERVICE 2014-2023 ($ MILLION)
  • 2. GLOBAL ASSAY KITS AND REAGENTS MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 3. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 4. GLOBAL COMPANION DIAGNOSTIC MARKET BY TECHNOLOGY 2014-2023($ MILLION)
  • 5. GLOBAL IN SITU HYBRIDIZATION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 6. GLOBAL POLYMERASE CHAIN REACTION MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 8. GLOBAL NEXT GENERATION SEQUENCING MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 9. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 10. GLOBAL COMPANION DIAGNOSTIC MARKET BY INDICATION 2014-2023($ MILLION)
  • 11. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-20232023 ($ MILLION)
  • 12. GLOBAL NEUROLOGY MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 13. GLOBAL INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 14. GLOBAL OTHER INDICATIONS MARKET BY GEOGRAPHY 2014-2023($ MILLION)
  • 15. NORTH AMERICA COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
  • 16. EUROPE COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
  • 17. ASIA PACIFIC COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
  • 18. REST OF THE COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
  • 2. GLOBAL ASSAY KITS AND REAGENTS MARKET 2014-2023($ MILLION)
  • 3. GLOBAL IN SITU HYBRIDIZATION MARKET 2014-2023($ MILLION)
  • 4. GLOBAL IN SITU HYBRIDIZATION MARKET 2014-2023($ MILLION)
  • 5. GLOBAL POLYMERASE CHAIN REACTION MARKET 2014-2023($ MILLION)
  • 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET 2014-2023($ MILLION)
  • 7. GLOBAL NEXT GENERATION SEQUENCING MARKET 2014-2023($ MILLION)
  • 8. GLOBAL OTHER TECHNOLOGIES GLOBAL ONCOLOGY MARKET 2014-2023($ MILLION)
  • 9. GLOBAL ONCOLOGY MARKET 2014-20232023 ($ MILLION)
  • 10. GLOBAL NEUROLOGY MARKET Y 2014-2023($ MILLION)
  • 11. GLOBAL INFECTIOUS DISEASES MARKET 2014-2023($ MILLION)
  • 12. GLOBAL OTHER INDICATIONS MARKET 2014-2023($ MILLION)
  • 13. UNITED STATES (U.S.) COMPANION DIAGNOSTIC MARKET 2014-2023($ MILLION)
  • 14. CANADA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 15. UNITED KINGDOM (UK) COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 16. FRANCE COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 17. GERMANY COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 18. RUSSIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 19. ROE COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 20. INDIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 21. CHINA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 22. JAPAN COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 23. AUSTRALIA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 24. ROAPAC COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 25. LATIN AMERICA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
  • 26. MENA COMPANION DIAGNOSTIC MARKET 2014-2023 ($ MILLION)
Back to Top